All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
How to treat high-risk follicular lymphoma
Grzegorz Nowakowski
Martin Dreyling
Michael Dickinson
Gilles SallesDuring a meeting of the Lymphoma Hub Steering Committee, Giles Salles chaired a discussion in which the steering committee debated how to treat high-risk follicular lymphoma. This included a discussion on how newly diagnosed high-risk follicular lymphoma should be treated, the impact of relapsed/refractory disease, and the standard of care.
How to treat high-risk follicular lymphoma.
Your opinion matters
On average, how many patients with chronic lymphocytic leukemia do you see in a month?